MIRLET7G

Summary

MIRLET7G (microRNA let-7g, HGNC:31485) is a microRNA gene on chromosome 3p21.2.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 406890 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:31485
Approved symbol	MIRLET7G
Name	microRNA let-7g
Location	3p21.2
Locus type	RNA, micro
Status	Approved
Aliases	hsa-let-7g
Ensembl gene	ENSG00000199150
Ensembl biotype	miRNA
OMIM	612102
Entrez	406890
RNAcentral	URS00003DBD40 — miRNA, 84 nt, 20 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000362280

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000362280 — 1 exons

Exon	Start	End
ENSE00001437043	52268278	52268361

Expression profiles

Bgee: expression breadth broad, 89 present calls, max score 82.00.

Top tissues by expression

89 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
skeletal muscle tissue	UBERON:0001134	82.00	gold quality
blood	UBERON:0000178	81.71	gold quality
bone marrow	UBERON:0002371	80.41	gold quality
placenta	UBERON:0001987	78.59	gold quality
liver	UBERON:0002107	78.53	gold quality
calcaneal tendon	UBERON:0003701	77.62	gold quality
muscle of leg	UBERON:0001383	77.39	gold quality
endometrium	UBERON:0001295	76.37	gold quality
epididymis	UBERON:0001301	75.85	gold quality
fundus of stomach	UBERON:0001160	75.59	gold quality
kidney	UBERON:0002113	74.89	gold quality
adrenal tissue	UBERON:0018303	74.67	gold quality
monocyte	CL:0000576	74.00	gold quality
rectum	UBERON:0001052	73.42	gold quality
uterus	UBERON:0000995	72.61	gold quality
islet of Langerhans	UBERON:0000006	71.98	gold quality
right atrium auricular region	UBERON:0006631	71.67	gold quality
heart	UBERON:0000948	70.96	gold quality
heart left ventricle	UBERON:0002084	70.72	gold quality
gastrocnemius	UBERON:0001388	70.67	gold quality
stomach	UBERON:0000945	69.71	gold quality
lower esophagus muscularis layer	UBERON:0035833	69.64	gold quality
lower esophagus	UBERON:0013473	69.58	gold quality
right adrenal gland	UBERON:0001233	69.26	gold quality
body of stomach	UBERON:0001161	69.25	gold quality
body of pancreas	UBERON:0001150	68.94	gold quality
tibial artery	UBERON:0007610	68.77	gold quality
left adrenal gland	UBERON:0001234	68.70	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	68.50	gold quality
left adrenal gland cortex	UBERON:0035825	68.48	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.62

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 40)

• analysis of let-7g microRNA processing inhibition by the developmentally regulated RNA-binding protein Lin28 (PMID:18550544)
• Raf kinase inhibitory protein suppresses a metastasis signalling cascade involving LIN28 and let-7 (PMID:19153603)
• hsa-let-7g may act as a tumor suppressor gene that inhibits HCC cell proliferation by downregulating the oncogene, c-Myc, and upregulating the tumor suppressor gene, p16(INK4A) . (PMID:20309945)
• the expression of miR-9 and let-7g could enhance the efficiency of radiotherapy for lung cancer treatment through the inhibition of NFkappaB1. (PMID:21464588)
• Data show that the let-7 (let-7d and let-7g) target IMP-1 stabilizes the mRNA of MDR1. (PMID:21618519)
• The mapped structure of pre-let-7g identifies regions of the terminal loop of pre-let-7g that physically interact with LIN28. (PMID:21815640)
• let-7g was identified as a unique member of the let-7 miRNA family that can serve as a prognostic biomarker in breast cancer. (PMID:21868760)
• oxLDL reduces the effect of let-7g on LOX-1 expression, resulting in HASMC proliferation and migration. (PMID:22135361)
• Data show that the zinc knuckle domains of Lin28 are sufficient to provide binding selectivity for pre-let-7 miRNAs. (PMID:22157959)
• Data indicate that microRNA let-7b, let-7g and miR-18b expressed in higher levels associated with tumours. (PMID:22821209)
• Expression of hyaluronan synthase 2 is repressed by let-7. (PMID:22871741)
• Lin28 uses two different TUTases to control let-7 expression.[MicroRNA Let-7, human] (PMID:22898984)
• these findings suggest that EWS mediates generation of mature let-7g from pre-let-7g. (PMID:22910415)
• study provides evidence that the miRNA hsa-let-7g inhibits LOX-1 expression/activation, proliferation and development of apoptosis in vascular cells (PMID:22956623)
• Data indicate that full length Lin28B is required to bind efficiently to pre-let-7g. (PMID:23063642)
• Regulation of autophagy and apoptosis in vascular smooth muscle cells is modulated by hsa-let-7g microRNA. (PMID:23305858)
• Our data indicate that Let-7g and miR-21 profiling combined with the determination of K-Ras mutational status may be considered a useful biomarker for a more effective molecular characterization and clinical management of NSCLC patients (PMID:23820752)
• Levels of let-7 g and miR-221 were higher in subjects with Metabolic Syndrome (MetS); the difference was more prominent in women. In women, increased expression of both microRNAs was associated with an increased number of MetS risk components. (PMID:24093444)
• In the training set, six serum miRNAs (miR-21, let-7g, miR-31, miR-92a, miR-181b, and miR-203) had significantly different expression levels between the CRCs and healthy controls. (PMID:24709885)
• It was found that reexpression of let-7g can inhibit the proliferation, migration, and invasion significantly, and that low expression of let-7g was significantly associated with poorer overall survival. (PMID:24724096)
• Expression of SUMO1/2/3 is dramatically enhanced by interferons through an miRNA-based mechanism involving the Lin28/let-7. (PMID:24942926)
• let-7g inhibits osteosarcoma cell malignant phenotype at least partly through targeting Aurora-B (PMID:25197332)
• let-7b/g inhibited AKT2 expression by directly binding to its 3’UTR, reduced p-AKT (S473) activation and suppressed expression of the downstream effector pS6. (PMID:25288334)
• Hsa-let-7 g miRNA increased the sensitivity of GC to oxidative stress by repression activation of DDR indirectly. Let-7 g improved the effects of X-rays on GC cells involving in DDR regulation as well. (PMID:25972194)
• KRAS 3’-UTR rs712 polymorphism interfered with has-let-7g/mRNA interaction, and showed that the minor allele was associated with an elevated risk for development of lung cancer in COPD. (PMID:26316738)
• The present study analyzed the effects of let-7g on hepatitis C virus infection in vitro, in clinical tissue and serum samples. let-7g expression is increased in serum and liver tissue of patients with sustained virologic response. (PMID:26489607)
• BAG3-mediated miRNA let-7g and let-7i inhibit proliferation and enhance apoptosis of human esophageal carcinoma cells by targeting the drug transporter ABCC10 and modulates cisplatin resistance. (PMID:26655271)
• Hepatitis B virus preS2 transcript can be targeted by host cellular let-7 g, which may mutually anatagonize the intrinsic let-7 g function and HBV replication. (PMID:26979389)
• we concluded that let-7g-5p inhibits epithelial-mesenchymal transition (EMT) consistent with reduction of glioma stem cell (GSC) phenotypes by targeting VSIG4 in glioblastoma. (PMID:27634309)
• data revealed that miR-let-7g exhibits anti-atherosclerotic activity, at least partially by targeting the LOX-1 signaling pathway. (PMID:28535009)
• The data suggest a relationship between aberrant methylation of hsa-let-7 g and disturbed folate metabolism in neural tube defects. (PMID:28631291)
• Concentrations of all let-7 miRNAs let-7a, let-7b, let-7c, let-7d, let-7e and let-7g were significantly higher in urine samples obtained from renal cell carcinoma (RCC) patients compared to healthy controls. (PMID:28694731)
• Data show that hepatitis B X-interacting protein (HBXIP) modulated Methyltransferase-like 3 (METTL3) by inhibiting miRNA let-7g, which down-regulated the expression of METTL3 by targeting its 3’UTR. (PMID:29174803)
• let7g exerts a LOX1independent antiaging effect on endothelial cells. (PMID:29393358)
• The relative expression of microRNA let-7g-5p was significantly upregulated in relapsed lung adenocarcinoma samples using FFPE tissue, which showed possible clinical utility as biomarkers predicting recurrence after curative surgery. (PMID:29923982)
• The pattern of let-7g expression change during the course of diabetes mirrors that of C-peptide levels, hinting at this microRNA’s association with the residual mass of the beta cells in patients with T1 diabetes mellitus. (PMID:30259606)
• Study identified hsalet7g to regulate the expression of TRPM6 in colorectal neoplasm. (PMID:30272358)
• extracellular microvesicle microRNA let-7g-5p and miR-497-5p were identified as putative novel predictive biomarkers of MAPKi treatment benefit in metastatic cutaneous malignant melanoma patients highlighting the potential relevance of assessing extracellular microvesicle microRNA during and after treatment to unravel novel mechanisms of resistance. (PMID:30399176)
• Has-let-7g is highly expressed in osteosarcoma tissues, and promotes the occurrence of osteosarcoma by down-regulating HOXB1 and activating NF-kappaB pathway. (PMID:30551492)
• Data suggest that let-7a and let-7g may be considered as predictive markers for severe pre-eclampsia (SPE). (PMID:31128089)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	mirlet7j	ENSDARG00000080515
mus_musculus	Mirlet7g	ENSMUSG00000065440
rattus_norvegicus	Mirlet7g	ENSRNOG00000050242

Paralogs (10): MIRLET7E (ENSG00000198972), MIRLET7A2 (ENSG00000198975), MIRLET7C (ENSG00000199030), MIRLET7F1 (ENSG00000199072), MIRLET7D (ENSG00000199133), MIRLET7A1 (ENSG00000199165), MIRLET7I (ENSG00000199179), MIRLET7F2 (ENSG00000208012), MIR98 (ENSG00000271886), MIRLET7A3 (ENSG00000283990)

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.